Somewhat Favorable News Coverage Somewhat Unlikely to Affect Grifols SA, Barcelona (GRFS) Stock Price

Media coverage about Grifols SA, Barcelona (NASDAQ:GRFS) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Grifols SA, Barcelona earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.5905108200107 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media stories that may have impacted Accern’s rankings:

Shares of Grifols SA, Barcelona (NASDAQ GRFS) opened at $23.98 on Friday. The company has a quick ratio of 1.39, a current ratio of 3.17 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $6,140.00, a P/E ratio of 25.78, a P/E/G ratio of 1.57 and a beta of 1.03. Grifols SA, Barcelona has a twelve month low of $16.37 and a twelve month high of $24.20.

GRFS has been the subject of a number of research reports. Zacks Investment Research lowered Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Citigroup initiated coverage on Grifols SA, Barcelona in a report on Tuesday, October 31st. They issued a “buy” rating for the company. UBS Group lowered Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a report on Friday, November 24th. Finally, BidaskClub lowered Grifols SA, Barcelona from a “sell” rating to a “strong sell” rating in a report on Saturday, December 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $24.00.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-grifols-sa-barcelona-grfs-stock-price.html.

About Grifols SA, Barcelona

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Insider Buying and Selling by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

What are top analysts saying about Grifols SA Barcelona? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols SA Barcelona and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit